U.S. drugmaker Pfizer announced it will offer its full portfolio of 500 medicines — including chemotherapies and oral cancer treatments — at not-for-profit prices to 45 of the world’s lowest-income countries. The move expands a program the company launched in May 2022 C.E. and marks one of the broadest voluntary access commitments ever made by a major pharmaceutical company.
At a glance
- Not-for-profit pricing: All 500 Pfizer products, including off-patent medicines, will be available at cost to 45 low-income countries under the expanded accord.
- Pfizer Accord program: Originally launched in 2022 C.E. with only patented medicines, the initiative now covers a far wider range of treatments, from cancer drugs to COVID-19 therapies.
- Global health access: The 45 countries included in the program are among the poorest in the world, where out-of-pocket drug costs have long put life-saving treatments out of reach for most patients.
What changed — and why it matters
When Pfizer first announced its “An Accord for a Healthier World” program in 2022 C.E., it covered a meaningful but limited set of patented drugs — including the COVID-19 antiviral Paxlovid and the breast cancer treatment Ibrance. The expansion changes the scale dramatically.
By adding off-patent medicines — drugs that generic manufacturers are already legally allowed to produce — Pfizer is signaling something broader: that pharmaceutical access in the world’s poorest nations is a systemic problem requiring systemic solutions, not case-by-case exceptions.
Chemotherapy and oral cancer drugs are among the treatments now included. In high-income countries, these medicines are considered standard of care. In much of sub-Saharan Africa and parts of South and Southeast Asia, they remain effectively unavailable to most patients — not because of patent restrictions, but because pricing structures were never designed with these markets in mind.
The 45 countries and what they share
The nations included in the accord are classified as low-income by the World Bank — places where average annual income is below roughly $1,085. Many are in sub-Saharan Africa, with others in South Asia and parts of the Pacific.
These are countries where noncommunicable diseases like cancer and heart disease are rising sharply, even as health systems remain chronically underfunded. The World Health Organization estimates that more than 80% of premature deaths from noncommunicable diseases now occur in low- and middle-income countries.
Access to medicines is not the only barrier — trained oncologists, diagnostic equipment, and treatment infrastructure all remain scarce. But pricing has been a foundational obstacle, and this accord directly addresses it.
A corporate commitment — with caveats
It is worth being clear about what this program is and isn’t. Not-for-profit pricing means Pfizer covers its costs but takes no margin in these markets — it does not mean the drugs are free. Countries and health ministries will still need procurement capacity and functioning supply chains to benefit from the accord.
There is also a question of durability. Voluntary corporate commitments can be modified or withdrawn. The Access to Medicine Foundation, which tracks pharmaceutical access globally, has long noted that binding frameworks and compulsory licensing mechanisms offer more reliable protections than goodwill pledges — however significant those pledges may be.
Still, the scale of this expansion is real. Including off-patent medicines in the accord removes a quiet but significant barrier: in many low-income countries, even decades-old cancer drugs have been priced beyond reach because no generic supply chain ever materialized. Médecins Sans Frontières and other organizations have documented this gap extensively.
A signal to the industry
Pfizer is the world’s largest pharmaceutical company by revenue. When it moves, others notice. The hope among global health advocates is that an accord of this scope creates competitive and reputational pressure on other major drugmakers to follow.
Vaccine equity efforts during the COVID-19 pandemic showed both what is possible when pharmaceutical companies engage directly with access questions — and how much ground remains. The expansion of the Pfizer accord doesn’t close that gap, but it moves the floor.
For the patients in those 45 countries who may now reach treatments they couldn’t before, the policy debate is secondary. What matters is whether the medicine is there when they need it.
Read more
For more on this story, see: Reuters
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Renewables now make up at least 49% of global power capacity
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
